BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 24922636)

  • 1. Immunohistochemical comparison of biomarker expression in biopsy and surgical specimens of non-small cell lung cancer.
    Okimoto T; Tsubata Y; Sutani A; Fuchita H; Koba N; Hotta T; Hamaguchi M; Miura K; Hamaguchi S; Ohe M; Kuraki T; Harada Y; Maruyama R; Miyamoto N; Kishimoto K; Isobe T
    Anticancer Res; 2014 Jun; 34(6):2755-61. PubMed ID: 24922636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
    Liu D; Nakashima N; Nakano J; Tarumi S; Matsuura N; Nakano T; Nii K; Tokunaga Y; Go T; Yokomise H
    Anticancer Res; 2017 May; 37(5):2501-2507. PubMed ID: 28476819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
    Shi Y; Chen L; Li J; Lü YL; Jiao SC
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer.
    Koh Y; Jang B; Han SW; Kim TM; Oh DY; Lee SH; Kang CH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Kim YW; Kim JH; Heo DS; Bang YJ
    J Thorac Oncol; 2010 Mar; 5(3):320-5. PubMed ID: 20087230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.
    Grossi F; Dal Bello MG; Salvi S; Puzone R; Pfeffer U; Fontana V; Alama A; Rijavec E; Barletta G; Genova C; Sini C; Ratto GB; Taviani M; Truini M; Merlo DF
    Dis Markers; 2015; 2015():302649. PubMed ID: 26663950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites.
    Gomez-Roca C; Raynaud CM; Penault-Llorca F; Mercier O; Commo F; Morat L; Sabatier L; Dartevelle P; Taranchon E; Besse B; Validire P; Italiano A; Soria JC
    J Thorac Oncol; 2009 Oct; 4(10):1212-20. PubMed ID: 19687761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer.
    Chiappori AA; Zheng Z; Chen T; Rawal B; Schell MJ; Mullaney BP; Bepler G
    J Thorac Oncol; 2010 Apr; 5(4):484-90. PubMed ID: 20107425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer.
    Zhang Y; Yang H; Qiu Y; Deng Q; Liu J; Zhao M; He P; Mo M; Zou X; He J
    Med Oncol; 2014 Mar; 31(3):803. PubMed ID: 24452282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy.
    Jiang H; Wang H; Wang S; Pei Z; Fu Z; Fang C; Wang J; Lu Q; Wang E; Li J
    Mol Med Rep; 2015 May; 11(5):3523-32. PubMed ID: 25573098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701).
    Bepler G; Zinner RG; Moon J; Calhoun R; Kernstine K; Williams CC; Mack PC; Oliveira V; Zheng Z; Stella PJ; Redman MW; Gandara DR
    Cancer; 2014 Aug; 120(15):2343-51. PubMed ID: 24752945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs.
    Micke P; Mattsson JS; Djureinovic D; Nodin B; Jirström K; Tran L; Jönsson P; Planck M; Botling J; Brunnström H
    J Thorac Oncol; 2016 Jun; 11(6):862-72. PubMed ID: 26872818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
    Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ
    Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy.
    Maus MK; Mack PC; Astrow SH; Stephens CL; Zeger GD; Grimminger PP; Hsiang JH; Huang E; Li T; Lara PN; Danenberg KD; Gandara DR
    J Thorac Oncol; 2013 May; 8(5):582-6. PubMed ID: 23470290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer.
    Zhang Q; Zhu X; Zhang L; Sun S; Huang J; Lin Y
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):839-46. PubMed ID: 25119181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer.
    Zheng Z; Li X; Schell MJ; Chen T; Boulware D; Robinson L; Sommers E; Bepler G
    Cancer; 2008 Jun; 112(12):2765-73. PubMed ID: 18442042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens.
    Loo PS; Thomas SC; Nicolson MC; Fyfe MN; Kerr KM
    J Thorac Oncol; 2010 Apr; 5(4):442-7. PubMed ID: 20195168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer.
    Tsoukalas N; Aravantinou-Fatorou E; Tolia M; Giaginis C; Galanopoulos M; Kiakou M; Kostakis ID; Dana E; Vamvakaris I; Korogiannos A; Tsiambas E; Salemis N; Kyrgias G; Karameris A; Theocharis S
    Anticancer Res; 2017 Apr; 37(4):1773-1778. PubMed ID: 28373440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bis Expression in Patients with Surgically Resected Lung Cancer and its Clinical Significance.
    Yeo CD; Park GS; Kang N; Choi SY; Kim HY; Lee DS; Kim YS; Kim YK; Park JG; Sung SW; Lee KY; Park MS; Yim HW; Kim SJ; Lee JH
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1365-70. PubMed ID: 25968616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
    Pesta M; Kulda V; Fiala O; Safranek J; Topolcan O; Krakorova G; Cerny R; Pesek M
    Anticancer Res; 2012 Nov; 32(11):5003-10. PubMed ID: 23155271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
    Ozdemir O; Ozdemir P; Veral A; Uluer H; Ozhan MH
    Asian Pac J Cancer Prev; 2013; 14(8):4679-83. PubMed ID: 24083725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.